Bayesian randomized clinical trials: A decision-theoretic sequential design

Canadian Journal of Statistics

Volumn 32, Issue 4, 2004, Pages 387-402

  Christen, J Andrés ^a   Müller, Peter ^b   Wathen, Kyle ^b   Wolf, Judith ^b  

^a CENTRO DE INVESTIGACIÓN EN MATEMÁTICAS   (Mexico)

^b MDACC ^*  (United States)

Author keywords

Backward induction; Clinical trials; Robustness; Utility functions

Indexed keywords

EID: 13244252368     PISSN: 03195724     EISSN: None     Source Type: Journal    
DOI: 10.2307/3316023     Document Type: Review

References (26)

1. F. J. Anscombe (1963). Sequential medical trials. Journal of the American Statistical Association, 58, 365-383.
2. J. O. Berger (1985). Statistical Decision Theory and Bayesian Analysis, Second Edition. Springer, New York.
3. D. A. Berry (1993). A case for Bayesianism in clinical trials. Statistics in Medicine, 12, 1377-1393.
4. D. A. Berry & D. K. Stangl (1996). Bayesian methods in health-related research. In Bayesian Biostatistics (D. A. Berry & D. K. Stangl, eds.), Statistics, Textbooks and Monographs 151, Marcel Dekker, New York, pp. 3-66.
5. S. M. Berry & J. B. Kadane (1997). Optimal Bayesian randomization. Journal of the Royal Statistical Society Series B, 59, 813-819.
6. J. Bryant & R. Day (1995). Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics, 51, 1372-1383.
7. D. P. Byar, D. A. Schoenfeld, S. B. Green, D. A. Amato, J. R. Anderson, R. Collins, R. Davis, V. De Gruttola, S. S. Ellenberg, D. M. Finkelstein, L. S. Freedman, M. Gail, C. Gatsonis, R. D. Gelber, D. Lagakos, M. Lefkopoulou, J. Peto, R. Peto, T. Peto, R. Simon, A. A. Tsiatis & M. Zelen (1990). Design considerations for AIDS trials. New England Journal of Medicine, 323, 1343-1348.
8. B. P. Carlin, J. B. Kadane & A. E. Gelfand (1998). Approaches for optimal sequential decision analysis in clinical trials. Biometrics, 54, 964-975.
9. K. Chaloner (1996). Elicitation of prior distributions. In Bayesian Biostatistics (D. A. Berry & D. K. Stangl, eds.), Statistics, Textbooks and Monographs 151, Marcel Dekker, New York, pp. 141-156.
10. M. H. DeGroot (1970). Optimal Statistical Decisions. McGraw-Hill, New York.
11. V. Hasselblad & A. M. Jarabek (1996). Dose-response analysis of toxic chemicals. In Bayesian Biostatistics (D. A. Berry & D. K. Stangl, eds.). Marcel Dekker, New York, pp. 235-259.
12. J. B. Kadane (1996). Bayesian Methods and Ethics in a Clinical Trial Design. Wiley, New York.
13. R. M. Kaplan (1995). Utility assessment for estimating quality-adjusted life years. In Valuing Health Care (F. A. Sloan, ed.), Cambridge University Press, pp. 31-60.
14. P. W. Lavori & R. Dawson (2000). A design for testing clinical strategies: biased adaptive within-subject randomization. Journal of the Royal Statistical Society Series A, 163, 29-38.
15. S. Piantadosi (1997). Clinical Trials: A Methodologic Approach. Wiley, New York.
16. S. J. Pocock (1977). Group sequential methods in the design and analysis of clinical trials. Biometrika, 64, 191-199.
17. S. J. Pocock (1983). Clinical Trials. Wiley, New York.
18. D. Rios-Insua, J. Martin, L. Proll, S. French & A. Salhi (1997). Sensitivity analysis in statistical decision theory: a decision analytic view. Journal of Statistical Computing and Simulation, 57, 197-218.
19. N. Sedransk (1996). Admissibility of treatments. In Bayesian Methods and Ethics in a Clinical Trial Design (J. B. Kadane, ed.), Wiley, New York, pp. 65-113.
20. D. J. Spiegelhalter, K. R. Abrams & J. P. Myles (2004). Bayesian Approaches to Clinical Trials and Health Care Evaluation. Wiley, Chichester.
21. D. J. Spiegelhalter, L. S. Freedman & M. K. B. Parmar (1996). Bayesian approaches to randomize trials. In Bayesian Biostatistics (D. A. Berry & D. K. Stangl, eds.), Statistics, Textbooks and Monographs 151, Marcel Dekker, New York, pp. 67-108.
22. N. Stallard, P. F. Thall & J. Whitehead (1999). Decision theoretic designs for phase II clinical trials with multiple outcomes. Biometrics, 55, 971-977.
23. S. Tedjarati, C. H. Baker, S. Apte, S. Huang, J. K. Wolf, J. J. Killion & I. J. Fidler (2002). Synergistic Therapy of Human Ovarian Carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon-α combined with paclitaxel. Clinical Cancer Research, 8, 2413-2422.
24. P. F. Thall (2001). Bayesian clinical trial design in a cancer center. Chance, 14, 23-28.
25. P. F. Thall, R. M. Simon & E. H. Estey (1995). Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Statistics in Medicine, 14, 357-379.
26. L. J. Wolfson, J. B. Kadane & M. J. Small (1996). Expected utility as a policy making tool: an environmental health example. In Bayesian Biostatistics (D. A. Berry & D. K. Stangl, eds.), Statistics, Textbooks and Monographs 151, Marcel Dekker, New York, pp. 261-277.